Search This Blog

Friday, November 1, 2019

Neovasc to file U.S. application for Reducer this quarter

After meeting with the FDA and “weighing all available options” Neovasc (NVCN) has decided to file a U.S. application for Neovasc Reducer by year-end.
It believes that data from the COSIRA trial, REDUCER-I European Post-Market study and multiple independent studies published in peer-reviewed journals should be sufficient to support a PMA application. It also intends to request an advisory committee meeting.
Reducer is a stent-like device used to treat refractory angina (chest pain caused by inadequate blood flow to the heart).

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.